Rising Incidence Of Inflammatory Bowel Disease Fuels Growth In The Anti-Inflammatory Therapeutics Market: Strengthening the Growth Trajectory of the Anti-Inflammatory Therapeutics Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Anti-Inflammatory Therapeutics Market Through 2025?
The market size for anti-inflammatory therapeutics has been consistently increasing over the past few years. The value is projected to rise from $114.71 billion in 2024 to $118.44 billion in 2025, presenting a compound annual growth rate (CAGR) of 3.3%. Factors contributing to this growth during the historic period include the widespread occurrence of chronic diseases, an aging populace, heightened awareness, and initiatives taken by the government.

What's the Projected Size of the Global Anti-Inflammatory Therapeutics Market by 2029?
The market size for anti-inflammatory therapeutics is anticipated to experience significant expansion in the upcoming years, with predictions placing its value at $144.05 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.0%. This predicted growth during the forecast period is credited to factors such as innovative treatment methods, a rise in health care spending, focus on unique diseases, as well as biologics and biosimilars. The anticipated trends during the forecast period encompass improvements in immunotherapy, the application of artificial intelligence (AI) and machine learning (ML) in the development of new drugs, and extension of indications.

View the full report here:
https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Top Growth Drivers in the Anti-Inflammatory Therapeutics Industry: What's Accelerating the Market?
The escalation in the number of inflammatory bowel disease cases is anticipated to fuel the expansion of the anti-inflammatory therapeutics market. This growth is attributed to the understanding that inflammatory bowel disease (IBD) is an enduring ailment that leads to inflammation within the digestive tract. Anti-inflammatory therapeutics are essential in the treatment of Crohn's disease as they minimize inflammation, manage the disease's symptoms and mitigate the risk of surgical treatment. As per the Oxford University Press (OUP), the educational branch of the University of Oxford, the incidence and prevalence of IBD in July 2023 are 10.9 per 100,000 person-years and 721 per 100,000 people respectively. This rise in the prevalence of such a disease therefore accelerates the progress of the anti-inflammatory therapeutics market. Extreme growth in the anti-inflammatory therapeutics market is predicted to be driven by the surge in the prevalence of autoimmune disorders. Autoimmune disorders entail a variety of medical conditions where the immune system, which normally shields the body from harmful externalities like bacteria and viruses, erroneously attacks the body's healthy cells and tissues. The escalating manifestation of autoimmune disorders is crucial to the growth of anti-inflammatory therapeutics. These therapeutics are frequently used in the treatment of autoimmune disorders. The aim of these medications is to curtail inflammation, regulate the immoderate response of the immune system and alleviate the symptoms stemming from autoimmune conditions. For example, reports by the UK-based Guardian Media Group in January 2022 revealed that in the UK, 4 million people battle autoimmune disorders, and globally, it is forecasted to rise by 3% to 9% annually. Additionally, the University of Oxford detailed in May 2023 that 10% of the global population was affected by autoimmune disorders. Consequently, the growth of the anti-inflammatory therapeutics market is driven by the rising prevalence of autoimmune disorders.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12861&type=smp

What Trends Will Shape the Anti-Inflammatory Therapeutics Market Through 2029 and Beyond?
Leading organizations in the anti-inflammatory therapeutics market are launching inventive drugs to consolidate their market standing. For example, Regeneron Pharmaceuticals Inc., a biotechnology firm from the United States, teamed up with Sanofi, a pharmaceutical and healthcare corporation from France, to unveil Kevzara (sarilumab) in February 2023. This is the first and only anti-inflammatory biologic recommended for adult patients suffering from polymyalgia rheumatic (PMR), an inflammatory rheumatic ailment, who either fail to respond sufficiently to corticosteroids or are unable to withstand corticosteroid tapering.

What Are the Main Segments in the Anti-Inflammatory Therapeutics Market?
The anti-inflammatory therapeutics market covered in this report is segmented -

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Anti-Inflammatory Biologics
2) By Indication: Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases, Other Inflammatory Diseases
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Distribution

Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Aspirin, Naproxen, Diclofenac, Celecoxib, Indomethacin, ket*oprofen
2) By Corticosteroids: Prednisone, Dexamethasone, Hydrocortisone, Methylprednisolone, Triamcinolone, Betamethasone
3) By Anti-Inflammatory Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Janus Kinase (JAK) Inhibitors, Monoclonal Antibodies, Recombinant Proteins, Fusion Proteins

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12861&type=smp

Which Top Companies are Driving Growth in the Anti-Inflammatory Therapeutics Market?
Major companies operating in the anti-inflammatory therapeutics market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Inc., Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd.

Which Regions Will Dominate the Anti-Inflammatory Therapeutics Market Through 2029?
North America was the largest region in the anti-inflammatory therapeutics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12861

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.